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Abstract
Circulating glucose levels are tightly regulated. To identify novel glycemic loci, we performed
meta-analyses of 21 genome-wide associations studies informative for fasting glucose (FG),
fasting insulin (FI) and indices of β-cell function (HOMA-B) and insulin resistance (HOMA-IR)
in up to 46,186 non-diabetic participants. Follow-up of 25 loci in up to 76,558 additional subjects
identified 16 loci associated with FG/HOMA-B and two associated with FI/HOMA-IR. These
include nine new FG loci (in or near ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3,
SLC2A2, PROX1 and FAM148B) and one influencing FI/HOMA-IR (near IGF1). We also
demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB/TMEM195 with type 2
diabetes (T2D). Within these loci, likely biological candidate genes influence signal transduction,
cell proliferation, development, glucose-sensing and circadian regulation. Our results demonstrate
that genetic studies of glycemic traits can identify T2D risk loci, as well as loci that elevate FG
modestly, but do not cause overt diabetes.
Impaired β-cell function and insulin resistance are key determinants of type 2 diabetes
(T2D). Hyperglycemia in the fasting state is one of the criteria that define the disease1, can
predict hard clinical endpoints in non-diabetic individuals2,3 and, when corrected in patients
with T2D, may help prevent microvascular4,5 and long-term macrovascular6,7
complications. To date, there are nearly 20 published loci reproducibly associated with
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T2D8, with most of them also associated with decreased insulin secretion9 due to defective
β-cell function or mass. Association studies for diabetes-related quantitative traits in non-
diabetic participants have also identified loci influencing fasting glucose (FG) levels, whose
effects appear to be mediated by impairment of the glucose-sensing machinery in β-cells10–
17.
We recently formed the Meta-Analyses of Glucose and Insulin-related traits Consortium
(MAGIC) to conduct large-scale meta-analyses of genome-wide data for continuous
diabetes-related traits in non-diabetic participants15. We aimed to identify additional loci
that influence glycemic traits in persons free of diabetes, and investigate their impact on
related metabolic phenotypes. We were also interested in understanding variation in the
physiological range and evaluating the extent to which the same variants influence
pathological FG variation and T2D risk. The initial MAGIC collaboration identified the FG/
T2D-associated locus MTNR1B15, which was also reported by others16,17; this finding
demonstrated that studies of continuous glycemic phenotypes in non-diabetic individuals
can complement the genetic analyses of diabetes as a dichotomous trait, and improve our
understanding of the mechanisms involved in β-cell function and glucose homeostasis. Here,
we extend our previous approach by performing meta-analyses of ~2.5M directly genotyped
or imputed autosomal SNPs from 21 genome-wide association studies (GWAS). These 21
cohorts include up to 46,186 non-diabetic participants of European descent informative for
FG, and 20 GWAS including up to 38,238 non-diabetic individuals informative for fasting
insulin (FI), as well as the surrogate estimates of β-cell function (HOMA-B) and insulin
resistance (HOMA-IR) derived from fasting variables by homeostasis model assessment18.
Follow-up of 25 lead SNPs in up to 76,558 additional individuals of European ancestry
identified nine novel genome-wide significant associations (empirically determined as
P<5×10−8)19 with FG and one with FI/HOMA-IR. Five of these novel loci also
demonstrated genome-wide significant evidence for association between the glucose-raising
allele and T2D risk in up to 40,655 cases and 87,022 non-diabetic controls.
The wealth of novel FG and HOMA-B loci contrast with the sole FI/HOMA-IR novel
finding and suggests a different genetic architecture for β-cell function and insulin
resistance. Furthermore, our data support the hypothesis that not all loci that influence
glycemia within the physiological range are also associated with pathological levels of
glucose and T2D risk.
RESULTS
Genome wide association meta-analysis of glycemic traits (Stage 1)
We conducted a two-stage association study in individuals of European descent (Online
Methods, Supplementary Figure 1, Supplementary Tables 1a and b). Because we sought to
identify variants that influence FG in the normal population, hyperglycemia in the diabetic
range exerts deleterious effects on β-cell function20,21, and treatment can confound glucose
and insulin measurements, we excluded individuals with known diabetes, on anti-diabetic
treatment, or with FG ≥7 mmol/L. We combined data from 21 Stage 1 discovery GWAS for
FG (N=46,186) and 20 GWAS for FI (N=38,238), HOMA-B (N=36,466) and HOMA-IR
(N=37,037), and analyzed associations for ~2.5M autosomal SNPs directly genotyped and
imputed22,23 from HapMap CEU sample data assuming an additive genetic effect for each
of the four traits.
Inverse variance weighted meta-analyses revealed 12 independent loci associated with FG
and/or HOMA-B at genome-wide significance levels (Table 1, Supplementary Table 2,
Supplementary Figure 2a–b). These included five novel associations for loci in or near
ADCY5, MADD, ADRA2A, CRY2 and FADS1 (Table 1, Figure 1a–j); four previously
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reported FG-associated loci in or near GCK, GCKR, G6PC2, and MTNR1B; the recently
reported DGKB/TMEM19524; and two loci in T2D susceptibility genes TCF7L2
(rs4506565, r2=0.92 with the previously reported SNP rs7903146) and SLC30A8
(rs11558471, r2=0.96 with the previously reported SNP rs13266634). Seven additional loci
had reproducible evidence for association with FG and/or HOMA-B across studies at the
arbitrary summary threshold of P<2×10−5 chosen to prioritize SNPs for follow-up (Table 1,
Supplementary Table 2). After excluding SNPs within the four previously genome-wide
significant FG loci GCK, GCKR, G6PC2 and MTNR1B, we still observed an excess of
small P-values compared to a distribution expected under the null hypothesis (Figure 2a–b),
suggesting that some of these additional loci are likely to represent novel FG and/or HOMA-
B loci that merit additional investigation.
Stage 1 analyses of FI and HOMA-IR revealed no loci that reached genome-wide
significance, but there were six loci with consistent evidence for association across study
samples at P<2×10−5 (Table 1, Supplementary Table 2, Supplementary Figure 2c–d).
Comparison of the observed P-values with the distribution expected under the null
hypothesis demonstrated an excess of small P-values which warrant further investigation
(Figure 2c–d).
Replication studies (Stage 2) and global (Stage 1 + Stage 2) meta-analysis for 25 loci
We carried forward to Stage 2 all independent loci with association with any of the four
traits at P<2×10−5, except for SNPs in the known T2D genes TCF7L2 and SLC30A8 for
which no further validation was sought (Table 1, Supplementary Table 2). We also included
the nominally associated top SNP from a strong biological candidate (IRS1, P=10−4 for
HOMA-IR) and a locus with P values that approached genome-wide significance in several
Stage 1 discovery cohorts (PLXDC2/NEBL), even though their overall Stage 1 P-values
were >2×10−5 (Table 1, Supplementary Table 2). In total, 25 loci were chosen for
replication.
We directly genotyped 25 variants in 26 additional Stage 2 studies with up to 63,850 non-
diabetic participants of European ancestry for FG, and 25 studies and up to 52,892
participants for FI, HOMA-IR and HOMA-B (Supplementary Table 1b, Online Methods).
We also obtained in silico replication data for 12,708 additional individuals from seven
studies for FG (9,372 participants and five studies for FI, HOMA-IR and HOMA-B), for a
total of up to 76,558 individuals for FG and 62,264 for FI, HOMA-IR and HOMA-B in
Stage 2 association analyses.
Our combined Stage 1 and 2 meta-analysis, including a total of up to 122,743 participants
for FG (98,372 for FI, HOMA-IR and HOMA-B) established genome-wide significant
associations for nine novel loci for FG and/or HOMA-B (ADCY5, MADD, CRY2,
ADRA2A, FADS1, PROX1, SLC2A2, GLIS3, FAM148B) and one for FI and HOMA-IR
(IGF1) (Table 1 and Figure 1a–j). We hereby replicate the recently reported loci DGKB/
TMEM195 (FG)24 and GCKR (FG, FI and HOMA-IR)11,12,25 at levels that exceed
genome-wide significance. Loci that had previously achieved genome-wide significant
associations with FG (G6PC2, MTNR1B and GCK) were also confirmed (Table 1).
We further conducted a global meta-analysis of cohort results adjusted for body mass index
(BMI), to test whether these diabetes-related quantitative trait associations may be mediated
by associations with adiposity. The adjustment for BMI did not materially affect the strength
of the associations with any of the traits (data not shown).
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Effect size estimates for genome-wide significant loci
We restricted our effect size estimates (Table 2, Supplementary Table 2) to the Stage 2
replication samples (up to N=76,558) to avoid inflation introduced by the discovery cohorts
(“winner’s curse”26). The previously identified loci G6PC2, MTNR1B and GCK showed
the largest effects on FG (0.075, 0.067 and 0.062 mmol/L per allele, respectively), with the
remaining loci showing smaller effects (0.008 to 0.030 mmol/L per allele, Table 2). The
proportion of variance in FG explained by the 14 FG loci with replication data (i.e. all FG
loci except for TCF7L2 and SLC30A8) ranged from 3.2–4.4% in six replication studies
providing this information. Because results from our largest unselected community-based
cohort (Framingham) were on the lower bound of these estimates (3.2%), we felt reassured
that the winner’s curse is not a major concern in this instance, and selected it to estimate the
proportion of heritability explained and the genotype score. With a heritability estimate of
30.4% in Framingham, these 14 loci explain a substantial proportion (~10%) of the inherited
variation in FG. If these same loci harbor additional independent variants (e.g. those due to
low frequency alleles not captured by this analysis) that also influence FG27, this estimate
of the heritability attributable to these loci is likely to be conservative.
We estimated the combined impact of the 16 loci associated with FG (the 14 loci included in
the genotype score plus TCF7L2 and SLC30A8) in some of the largest cohorts
(Framingham, NFBC 1966 and ARIC) by constructing a genotype score equal to the sum of
the expected number of risk alleles at each SNP weighted by their effect sizes (see Online
Methods). FG levels were higher in individuals with higher genotype scores (Figure 3), with
mean differences of ~0.4 mmol/L (5.93 vs 5.51 mmol/L in NFBC 1966; 5.36 vs 5.03 mmol/
L in Framingham; 5.70 vs 5.29 mmol/L in ARIC) comparing individuals with a score of 23
or higher (5.6% of the sample) to those with a genotype score of 12 or lower (2.9% of the
sample). The 0.4 mmol/L (7.2 mg/dl) difference between the two tails of the distribution of
risk score in the population (top 5.6% vs bottom 2.9%) is of clinical relevance, as it
represents a shift of approximately 25 centile points in the distribution of FG. Prospective
evidence has shown that a difference of this magnitude in FG is associated with a relative
risk of 1.54–1.73 for future T2D, accounting for other risk factors28. The impact of
individual SNPs on FG in the combined discovery and replication samples is shown in
Supplementary Figure 3a–p.
We also analyzed data from 1,602 white European children aged 5.9–17.2 from two studies.
Though directionally consistent with observations in adults, some effect size estimates were
of smaller magnitude (data not shown). As in adults, the largest effect sizes were observed
for risk alleles in GCK (beta=0.085; P=1.2×10−5; N=1,602), G6PC2 (beta=0.062;
P=1.9×10−4; N=1,582) and MTNR1B (beta=0.033; P=0.058; N=1,309).
Impact of reproducibly associated loci on additional glycemic traits
We sought to investigate all 17 loci associated with FG/HOMA-B or FI/HOMA-IR at
genome-wide significance for their effects on other continuous glycemic traits. While most
of the 16 loci associated with FG are also strongly associated with HOMA-B (Tables 1 and
2), the associations between FG loci and FI were at best weak; GCKR is the only locus
reaching genome-wide significant associations for both FG/HOMA-B and FI/HOMA-IR,
with the glucose-raising C allele being associated with increased FI (global P=3.6×10−20)
and HOMA-IR (global P=3.0×10−24). These patterns are consistent with the gross trait
correlations obtained in Framingham for FG and HOMA-B (r=−0.43) and for FG and FI
(r=0.25).
Impairment of glucose homeostasis may be characterized by elevated FG or FI, elevated 2-
hour glucose or 2-hour insulin post-oral glucose tolerance test (OGTT), or elevated glycated
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hemoglobin (HbA1c). We tested associations of each of the 17 loci in a subset of MAGIC
cohorts with GWAS data informative for these traits. Since HbA1c is a measure of average
glycemia over the preceding 2–3 months, we hypothesized that if an association with
additional traits was present it should be directionally consistent. The three loci with the
largest effect sizes on FG (G6PC2, MTNR1B and GCK) all showed genome-wide
significant and directionally consistent associations with HbA1c, with DGKB/TMEM195,
ADCY5, SLC2A2, PROX1, SLC30A8 and TCF7L2 showing nominal (P<0.05) evidence of
directionally consistent association (Table 2). The FG-raising alleles at TCF7L2, SLC30A8,
GCK and ADCY5 were associated (P<0.0002) with increased 2-hour glucose (Table 2); a
parallel MAGIC project reports the genome-wide significant association with 2-hour
glucose of another ADCY5 SNP in strong linkage disequilibrium (LD) with our lead SNP
(r2=0.82)29. Consistent with previous reports that the FG-raising allele is associated with
greater insulin release during OGTT11,12,30, the FG-raising allele in GCKR was associated
with lower 2-hour glucose.
Testing of these loci for association with T2D as a dichotomous trait in up to 40,655 cases
and 87,022 non-diabetic controls demonstrated that the FG-raising alleles at seven loci
(ADCY5, PROX1, GCK, GCKR and DGKB/TMEM195 and the known T2D genes
TCF7L2 and SLC30A8), are robustly associated (P<5×10−8) with increased risk of T2D
(Table 2); the association of a highly correlated SNP in ADCY5 with T2D in partially
overlapping samples is reported by our companion manuscript29. We found less significant
T2D associations (P<5×10−3) for variants in or near CRY2, FADS1, GLIS3 and FAM148B
(Table 2). These data clearly show that loci with very similar FG effect sizes may have very
different T2D risk effects (see for example ADCY5 and MADD in Table 2).
Given that several alleles associated with higher FG levels were also associated with
increased T2D risk and that the T2D genes TCF7L2 and SLC30A8 showed association with
FG, we systematically investigated association of all established T2D loci with the same
four fasting diabetes-related quantitative traits. We found directionally consistent nominal
associations (P<0.05) of T2D risk alleles with higher FG for 11 of 18 established T2D loci,
including MTNR1B (Supplementary Table 3). These data demonstrate that a large T2D
effect size does not always translate to an equivalently large FG effect in non-diabetic
persons, as clearly highlighted when contrasting the remarkably small effects of TCF7L2 on
FG compared to MTNR1B (Table 2).
Impact of reproducibly associated loci on additional metabolic traits
Next, we used available GWAS results for additional metabolic phenotypes (BMI from
GIANT31, blood pressure from Global BPGen32, and lipids from ENGAGE33), to assess
the impact of the newly discovered glycemic loci on these traits. None of the novel loci had
significant (P<0.01) associations with BMI or blood pressure (Table 3). Interestingly, the
FADS1 glucose-raising allele was associated with increased total cholesterol (P=2.5×10−6),
low-density lipoprotein cholesterol (P=8.5×10−6) and high-density lipoprotein cholesterol
(P=2.9×10−5), but lower triglyceride levels (P=1.9×10−6) (Table 3); a consistent association
of this locus with lipid levels has been previously reported34. The FG-associated variant in
MADD was not associated with lipid levels and is not in LD (r2<0.1) with a previously
reported high-density lipoprotein cholesterol SNP (rs7395662)33, suggesting two
independent signals within the same locus, one affecting lipid levels and the other FG levels
(Table 3).
Potential functional roles of novel associated loci
We investigated the likely functional role of genes mapping closest to the lead SNPs using
several sources of data, including human disease databases, evidence from animal models
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and bioinformatic analyses (see Box, Online Methods and Supplementary Table 4). The
newly discovered and established glycemic loci represent various biological functions:
signal transduction (DGKB/TMEM195, ADCY5, FADS1, ADRA2A, SLC2A2, GCK,
GCKR, G6PC2, IGF1); cell proliferation and development (GLIS3, MADD, PROX1);
glucose transport and sensing (SLC2A2, GCK, GCKR, G6PC2); and circadian rhythm
regulation (MTNR1B, CRY2). All of these pathways represent further avenues for
physiological characterization and possible therapeutic intervention. However, we note that
other genes could be causal (Box and Supplementary Table 4) and further experimental
evidence will be needed to link unequivocally specific genes with phenotypes.
Expression analyses
We measured expression of the genes mapping closest to our lead SNPs (in DGKB/
TMEM195, ADCY5, MADD, its neighboring gene SLC39A13 [a member of a family of
zinc transporters mapping ~45 kb from the MADD lead SNP], ADRA2A, FADS1, CRY2,
SLC2A2, GLIS3, PROX1 and FAM148B) in human pancreas and other metabolically
relevant tissues (Supplementary Figure 4a). While there was evidence of expression in
human islets for nearly all genes tested (with the sole exception of TMEM195), we found
that DGKB and MADD were most strongly expressed in brain, SLC2A2, FADS1,
TMEM195 and PROX1 in liver and ADCY5 in heart, while SLC39A13, ADRA2A and
CRY2 were broadly expressed. Strikingly, FAM148B was highly expressed in the whole
pancreas with lower levels in isolated islets, suggesting that it is also present in exocrine
cells. A duplicate experiment in a different laboratory obtained similar results
(Supplementary Figure 4b). We further examined expression of these transcripts in flow-
sorted human β-cells from two separate individuals and documented β-cell expression for all
but TMEM195, with SLC39A13, CRY2, GLIS3 and PROX1 being particularly highly
expressed in these cells (Supplementary Figure 4c). Expression levels in metabolically
relevant tissues for DGKB (β cells) and TMEM195 (liver) provide equally credible evidence
for their respective candidacies as the causal gene at these loci. Furthermore, based on its
relatively high expression levels in the β cell, SLC39A13 (neighboring gene to MADD)
constitutes an intriguing candidate gene that may merit further investigation.
Potential causal variants, eQTLs and copy number variants
Our results interrogate only a fraction of the common variants in any given genomic region;
we therefore expect that for the majority of the loci here described the underlying causal
variant has yet to be identified. Nevertheless for some there are intriguing possible SNP
candidates: in SLC2A2 the lead SNP (rs11920090) is in perfect LD (r2 = 1.0) with rs5400
(Stage 1 discovery association P=5.9×10−6), which codes for the amino acid substitution
T110I, predicted to be “possibly damaging” by PolyPhen35 and PANTHER (Pdel= 0.92)36.
In GCKR the lead SNP is in strong LD (r2=0.93) with rs1260326, encoding P446L, a non-
synomymous variant previously associated with the same traits30 and predicted by
PolyPhen to be “probably damaging”. A recent functional study has demonstrated that this
variant indirectly leads to increased GCK activity, resulting in the observed effects on FG
and triglyceride levels37. Both SLC2A2 T110I and GCKR P446L were predicted
“tolerated” by SIFT38, highlighting the difficulties in obtaining consensus functional
predictions from different informatic approaches.
We used publicly available eQTL datasets for liver39, cortex40 and Epstein-Barr virus-
transformed lymphoblastoid cell lines41 to explore additional possible causal mechanisms
testing for association between replicated loci and mRNA expression levels of nearby genes
(Online Methods). The lead SNP in FADS1, rs174550, is in strong LD (r2=0.80) and close
proximity (130 bp) to rs174548, a SNP highly associated with FADS1 mRNA expression
levels in liver (P=1.7×10−5) and with FADS2 mRNA expression levels in lymphoblastoid
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cells (P=3.1×10−4). SNP rs174548 has also been associated (up to P=4.5×10−8) with a
number of serum glycerophospholipid concentrations in a GWAS investigating metabolomic
profiles42 and rs174550 also demonstrated strong associations (P<5.2×10−7) with the same
metabolites (data not shown). These results are substantiated by previous work associating
SNPs in this region with the fatty acid composition of phospholipids43. The latter suggest
the minor allele variant of rs174550 results in a reduced efficiency of the fatty acid delta-5
desaturase reaction42. Finally, bioinformatic analysis identifies a perfect proxy, rs174545
(r2=1 with rs174550), whose glucose-raising allele abolishes a predicted miR-124 target site
(see Online Methods). Taken together, these data support the hypothesis that not only fatty
acid levels, but also their precise composition and degree of desaturation, may influence
glucose homeostasis.
Although our study was not designed to explicitly investigate the impact of copy number
variation on glycemic traits, we took advantage of existing data44 to investigate whether any
of our lead SNPs are in LD with common, diallelic copy number polymorphisms (CNPs)
mapping within a 1Mb window. Of the FG loci, only DGKB/TMEM195 has a validated,
common CNP affecting sequence within 1 Mb of the index SNP44. Despite the proximity of
this CNP to the associated SNP (~25 kb), the CNP is essentially uncorrelated with the index
SNP (r2=0.01 in HapMap CEU) and is therefore unlikely to explain the observed FG
association.
DISCUSSION
In this meta-analysis of 21 Stage 1 discovery GWAS cohorts followed by targeted Stage 2
replication of 25 loci in 33 additional cohorts (totaling up to 122,743 non-diabetic
participants), we report the novel genome-wide significant associations of SNPs in or near
ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3, SLC2A2, PROX1 and FAM148B
with FG and one SNP near IGF1 with FI and HOMA-IR. We have also confirmed
associations of variants in GCK, GCKR, G6PC2 and MTNR1B with FG, and achieved
genome-wide significance for the recently reported DGKB/TMEM195 locus24 and for
variants in the known T2D-associated TCF7L2 and SLC30A8. All of the FG-associated
SNPs demonstrate consistent nominal associations with HOMA-B; and those in GCK,
G6PC2, MTNR1B, DGKB/TMEM195, ADCY5, FADS1 and GLIS3 do so at genome-wide
significant levels. As previously reported11,12,30, GCKR is also associated with FI and
HOMA-IR.
Importantly, in addition to the established T2D-associated loci TCF7L2, SLC30A8 and
MTNR1B, five of the loci that are associated with elevated FG levels in non-diabetic
individuals (ADCY5, GCK, GCKR, PROX1 and DGKB/TMEM195) also increase the risk
of T2D in separate T2D case-control studies. However, this overlap is incomplete and
highlights that the magnitude of the effect on FG is not predictive of the effect on T2D risk,
as shown when comparing FG and T2D effect sizes for MTNR1B and TCF7L2, or for
ADCY5 and MADD (Table 2). The latter two loci have similar effect sizes on FG and
similar allele frequencies, and yet the former is robustly associated with T2D risk (OR 1.12,
P=5.5×10−21) while the latter is not (OR 1.01, P=0.3) in the same samples. This suggests
that not all loci associated with FG within the “physiological” range are also associated with
“pathological” FG levels and T2D risk. Thus, variation in FG in healthy individuals is not
necessarily an endophenotype for T2D, which posits the hypothesis that the mechanism by
which glucose is raised, rather than a mere elevation in fasting glucose levels, is a key
contributor to disease progression. On the other hand, we cannot rule out the existence of
protective variants in loci where elevated FG does not progress to manifest T2D, or the
effect of cohort selection in the detection of the loci with variable effects on FG and T2D
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risk. Nevertheless, this work shows that targeting quantitative traits in GWAS searches can
help identify genetic determinants of overt disease.
With regard to insulin resistance, our analyses resulted in only one novel genome-wide
significant locus associated with FI and HOMA-IR. The associated SNP rs35767 is 1.2 kb
upstream of IGF1, raising the possibility that it may influence IGF1 expression levels (we
have found no direct support for this notion in the limited eQTL data available). Although
not reaching genome-wide-significance, we note that SNP rs4675095 in the insulin receptor
substrate-1 gene (IRS1) was also associated with HOMA-IR (P=4.6×10−3), which given
IRS1’s excellent biological credentials will warrant further investigation. This SNP is not in
LD with the widely studied missense SNP G972R (rs1801278) nor with the newly
discovered T2D SNP rs294364145, whose C risk allele was only nominally associated with
increased FI (P=0.02) and HOMA-IR (P=0.04) in our discovery dataset. The previously
reported associations of SNPs in PANK1 with fasting insulin24 did not receive strong
support in our discovery cohorts (P=0.04 and 0.17 for rs11185790 and rs1075374,
respectively).
Notably, our large-scale meta-analyses produced more than a dozen robust associations with
FG and only two with FI/HOMA-IR (GCKR and IGF1). Although the somewhat smaller
sample size for insulin may have contributed to this discrepancy, a comparison of the
similarly-powered HOMA-B and HOMA-IR analyses reveals associations with HOMA-B
several orders of magnitude more significant than those seen with HOMA-IR (Figure 2).
Because insulin itself is a component of the numerator in both measures, one cannot
attribute this discrepancy to technical differences in insulin measurements across cohorts.
Similarly, because the QQ plots are very similar for FI and HOMA-IR, we do not believe
that the use of a mathematical formula (HOMA-IR) rather than a direct measurement (FI)
has affected our analyses substantially. HOMA-B and HOMA-IR have comparable
heritability estimates (0.26 and 0.27 in Framingham respectively) and their correlation is
significant (r=0.55 in Framingham). Thus, not only there may be a difference in the identity
of specific genetic determinants for each trait46, but rather the genetic architecture may be
distinct for each trait, with more modest effects, fewer loci, rarer variants or a stronger
environmental modification underlying HOMA-IR. In addition, HOMA-IR (which is
composed of fasting values) is an imperfect estimate of global insulin resistance, as it
addresses mostly hepatic sensitivity to insulin and is partially affected by β-cell function: its
heritability is lower than insulin sensitivity derived from the minimal model47. Exploration
of gene × environment interactions and analysis of datasets that include 2-hour glucose and
insulin values may reveal other genetic factors that increase insulin resistance in humans29.
In conclusion, a large-scale meta-analysis of GWAS has identified ten novel loci associated
with glycemic traits whose in-depth physiological investigation should further our
understanding of glucose homeostasis in humans and may reveal novel pathways for
diabetes therapeutics.
BOX: GENES NEAREST TO LOCI ASSOCIATED WITH FASTING DIABETES-
RELATED QUANTITATIVE TRAITS
DGKB/TMEM195 – This locus was recently reported to be associated with FG24; here
we report genome-wide significant replication of that finding and evaluate the genes
mapping closest to the lead SNP in further detail. DGKB encodes the β (1 of 10) isotype
of the catalytic domain of diacylglycerol kinase, which regulates the intracellular
concentration of the second messenger diacylglycerol. In rat pancreatic islets glucose
increases diacylglycerol49, which activates protein kinase C (PKC) and thus potentiates
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insulin secretion50. TMEM195 encodes transmembrane protein 195, an integral
membrane phosphoprotein highly expressed in liver.
ADCY5 encodes adenylate cyclase 5, which catalyzes the generation of cAMP. Upon
binding to its receptor in pancreatic β cells, glucagon-like peptide 1 (GLP-1) induces
cAMP-mediated activation of protein kinase A, transcription of the proinsulin gene and
stimulation of insulin secretory processes51.
MADD encodes mitogen-activated protein kinase (MAPK) activating death domain, an
adaptor protein that interacts with the tumor necrosis factor α receptor to activate MAPK.
Both PKC and MAPK have been implicated in the proliferation of β cells induced by
GLP-151, suggesting that DGKB and MADD may contribute to β-cell mass and insulin
secretion in this manner as well. Also in this region, SLC39A13 encodes a putative zinc
transporter required for connective tissue development and BMP/TGF-β signaling52.
NR1H3 encodes the liver X receptor alpha (LXRA) protein, which contains the retinoid
response element. Glucose stimulates the transcriptional activity of LXR, which acts as a
molecular switch that integrates hepatic glucose metabolism and fatty acid synthesis53.
ADRA2A encodes the α2A adrenergic receptor, which is expressed in β cells and whose
activation leads to an outward potassium current independent of the islet KATP channel,
thus possibly modifying insulin release54. Mice with null mutations display abnormal
glucose homeostasis in addition to cardiac hypertrophy and abnormal heart rate and
blood pressure.
FADS1 encodes fatty acid desaturase 1, which catalyzes the biosynthesis of highly
unsaturated fatty acids from precursor essential polyunsaturated fatty acids. One such
product is arachidonic acid; in rodent β cells, arachidonic acid liberated by phospholipase
A2 augments glucose-mediated insulin release55. Two other members of the same
family, FADS2 and FADS3, also reside in this region. By directing fatty acids down this
metabolic pathway, increased activity of these enzymes may lower circulating
triglyceride concentrations.
CRY2 encodes cryptochrome 2, an integral component of the mammalian circadian
pacemaker56. Mice with null mutations in this gene present with abnormal circadian
rhythmicity and several metabolic abnormalities including impaired glucose tolerance,
increased insulin sensitivity, decreased body weight and adipose tissue, and abnormal
heart rate. Together with MTNR1B15–17 this is the second circadian gene associated
with FG in humans, contributing further evidence to this emerging pathway regulating
glucose homeostasis57. In the same region, MAPK8IP1 encodes the scaffolding protein
JIP1. Cross-talk between JIP1 and JIP3 has been implicated in the regulation of ASK1-
SEK1-JNK signaling during glucose deprivation58. A missense mutation in this gene
(S59N) segregates with diabetes in one family affected with a Mendelian form of the
disease59.
SLC2A2 encodes the GLUT2 transporter responsible for transport of glucose into β cells
and triggering the glucose-mediated insulin secretion cascade. In humans, recessive
mutations in this gene lead to Fanconi-Bickel Syndrome, a rare disorder characterized by
hepatorenal glycogen accumulation, proximal renal tubular dysfunction and impaired
utilization of glucose and galactose60; mouse mutants also display hyperglycemia and
abnormal glucose homeostasis61.
GLIS3 encodes the transcription factor GLIS family zinc finger 3 isoform, a Krüppel-like
zinc finger protein that both activates and represses transcription and participates in β-
cell ontogeny62,63. Functional mutations in this gene cause a syndrome of neonatal
diabetes and congenital hypothyroidism63. Polymorphisms within this gene have
recently been associated with type 1 diabetes risk (t1dgc.org).
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PROX1 encodes the prospero homeobox protein 1, a novel co-repressor of hepatocyte
nuclear factor 4α64 that plays a crucial role in β-cell development; mutations in its target
gene HNF4A cause maturity-onset diabetes of the young, type 165.
FAM148B encodes the nuclear localized factor 2 (NLF2). It is expressed in endothelial
cells and up-regulated by pro-inflammatory cytokines66. As shown here, it has a high
level of expression in the pancreas, although its putative molecular connection with
glucose homeostasis is presently unclear.
IGF1 encodes the insulin-like growth factor 1, the sole genome-wide significant locus
associated with HOMA-IR in our study. Humans and mice null for igf1 display abnormal
glucose homeostasis, with insulin resistance, increased circulating insulin and
insensitivity to growth hormone67.
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Figure 1.
Regional plots of ten novel genome-wide significant associations. For each of the ADCY5
(a), MADD (b), ADRA2A (c), FADS1 (d), CRY2 (e), SLC2A2 (f), GLIS3 (g), PROX1 (h),
FAM148B (i) and IGF1 (j) regions, directly genotyped and imputed SNPs are plotted with
their meta-analysis P values (as –log10 values) as a function of genomic position (NCBI
Build 35). In each panel, the Stage 1 discovery SNP taken forward to Stage 2 replication is
represented by a blue diamond (with global meta-analysis P value), with its Stage 1
discovery P value denoted by a red diamond. Estimated recombination rates (taken from
HapMap) are plotted to reflect the local LD structure around the associated SNPs and their
correlated proxies (according to a white to red scale from r2 = 0 to 1, based on pairwise r2
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values from HapMap CEU). Gene annotations were taken from the University of California
Santa Cruz genome browser.
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Figure 2.
Quantile-quantile (Q-Q) plots for fasting glucose (FG) (a), β-cell function by homeostasis
model assessment (HOMA-B) (b), fasting insulin (FI) (c), and insulin resistance by
homeostasis model assessment (HOMA-IR) (d). In each plot, the expected null distribution
is plotted along the red diagonal, the entire distribution of observed P values is plotted in
black, and a distribution that excludes the ten novel findings in Figure 1 is plotted in green.
For FG and HOMA-B, the distribution that excludes the four genome-wide significant FG-
associated loci (GCK, GCKR, G6PC2 and MTNR1B) is plotted in blue. A comparison of
the observed P values for each trait shows that FG/HOMA-B associations are much more
likely to be detected than FI/HOMA-IR associations.
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Figure 3.
Variation in levels of fasting glucose depending on the number of risk alleles at novel loci,
weighted by effect size in an aggregate genotype score for the Framingham Heart Study.
The bar plots show the average and standard error of fasting glucose in mmol/L for each
value of the genotype score based on the regression coefficient (right Y axis), and the
histogram denotes the number of individuals in each genotype score category (left Y axis).
Comparable results were obtained for the NFBC 1966 and ARIC cohorts. On average, the
range spans ~0.4 mmol/L (~7.2 mg/dl) from low to high genotype score.
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